ClinicalTrials.gg
CompletedNCT02842242PIONEER-HCMUpdated Jun 8, 2021Results posted

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

A Phase 2 interventional study of MYK-461 in Cardiomyopathy, Hypertrophic Obstructive and Left Ventricular Outflow Tract Obstruction, sponsored by MyoKardia, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by MyoKardia, Inc. (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
19th of 21
21 · median 75
Started
2016
the only one that year
Phase 2
3 of 21
none open now
Registered
3rd of 21
by date
Lead sponsor
5 of 21
MyoKardia, Inc.

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 19th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 2, and was the 3rd registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years.

03

Conditions studied

  • Cardiomyopathy, Hypertrophic Obstructive
  • Left Ventricular Outflow Tract Obstruction
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with HCM (hypertrophied and non-dilated left ventricle in absence of systemic or other known cause), with LV wall thickness ≥ 15 mm at time of initial diagnosis or ≥ 13 mm with a positive family history of HCM.
  • Age 18-70
  • 18-37kg/m2
  • Documented ≥ 55% at the Screening visit as determined by the investigator and the site's echocardiography laboratory.
  • Resting LVOT gradient ≥ 30 mg Hg and post-exercise peak LVOT gradient ≥ 50 mm Hg
  • functional class II or higher

Key Exclusion Criteria:

  • History of sustained ventricular tachyarrhythmia.
  • History of syncope with exercise within past 6 months.
  • Active infection.
  • Persistent atrial fibrillation or atrial fibrillation at Screening or history of paroxysmal atrial fibrillation with resting rate document > 100bpm within 1 year of screening.
  • Has Fridericia (QTcF) > 500 ms, or any other abnormality considered by the investigator to pose a risk to subject safety (e.g. second degree atrioventricular block type II).
  • Aortic stenosis or fixed subaortic obstruction.
  • History of LV systolic dysfunction (LVEF \< 45%) at any time during their clinical course.
  • History of obstructive coronary artery disease.
  • History or evidence of any other disorder, condition, or disease that, in the opinion of the investigator or MyoKardia physician, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Part A: Ongoing therapy with beta blockers, calcium channel blockers, or disopyramide. Subjects on any of these medications who, in the opinion of the investigator, can safely be withdrawn are eligible as long as medication is discontinued at least 14 days prior to the Screening visit.
  • Part B: Ongoing therapy with calcium channel blockers or disopyramide. Subjects on any of these medications who, in the opinion of the investigator, can safely be withdrawn are eligible as long as medication is discontinued at least 14 days prior to the Screening visit.
  • Prior treatment with cardiotoxic agents such as doxorubicin or similar, or current treatment with antiarrhythmic drugs that have negative inotropic activity, e.g. flecainide or propafenone.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Open Label

    MYK-461

    Drug: MYK-461

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12

    Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg

    LVOT gradients are assessed after a treadmill stress test by echocardiography.

    Time frame: Baseline and Week 12

  2. Change in Dyspnea Symptom Score From Baseline to Week 12

    The scale name is Dyspnea Numeric Rating Scale (NRS). It is intended to measure how much shortness of breath you have had in the past week. 0 = no shortness of breath and 10 = shortness of breath as the worst possible.

    Time frame: Baseline and Week 12

  3. Change in Peak VO2 From Baseline to Week 12

    Peak VO2 is assessed using a cardiopulmonary exercise test.

    Time frame: Baseline and Week 12

  4. Change in VE/VCO2 From Baseline to Week 12

    VE/VCO2 is assessed from cardiopulmonary exercise testing results.

    Time frame: Baseline and Week 12

  5. Change in Resting LVEF From Baseline to Week 12

    LVEF is assessed by echocardiography.

    Time frame: Baseline and Week 12

  6. Change in LV Fractional Shortening (LVFS) From Baseline to Week 12

    LVFS is assessed using echocardiography measures.

    Time frame: Baseline and Week 12

  7. Change in Global Longitudinal Strain (GLS) From Baseline to Week 12

    GLS is assessed using echocardiography measures.

    Time frame: Baseline and Week 12

  8. Change in Post-exercise Peak LVOT Gradient From Week 12 to Week 16

    Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.

    Time frame: Weeks 12 and 16

Other outcomes

  1. Change in NYHA Functional Class From Baseline to Week 12

    Time frame: Baseline and Week 12

  2. Change in KCCQ OSS From Baseline to Week 12

    Time frame: Baseline and Week 12

  3. Change in NT-proBNP From Baseline to Week 12

    Time frame: 12 weeks

  4. Number of Subjects Achieving an LVOT Gradient Response of Post-exercise Peak Gradient < 10 mmHg at Week 12

    Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.

    Time frame: Baseline and Week 12

07

Results

Posted Feb 5, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort ACohort B
Started1110
Completed1010
Not completed10

Outcome measures

PrimaryChange in Post-exercise Peak LVOT Gradient From Baseline to Week 12

Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.

Time frame:
Baseline and Week 12
Reported as:
Mean · mm Hg
Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12
mm HgCohort ACohort B
Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12-89.5 (-138.3 to -40.7)-25.0 (-47.1 to -3.0)
SecondaryNumber of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg

LVOT gradients are assessed after a treadmill stress test by echocardiography.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg
ParticipantsCohort ACohort B
Number of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg80
SecondaryChange in Dyspnea Symptom Score From Baseline to Week 12

The scale name is Dyspnea Numeric Rating Scale (NRS). It is intended to measure how much shortness of breath you have had in the past week. 0 = no shortness of breath and 10 = shortness of breath as the worst possible.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change in Dyspnea Symptom Score From Baseline to Week 12
units on a scaleCohort ACohort B
Change in Dyspnea Symptom Score From Baseline to Week 12-3.1 (-4.1 to -2.1)-3.0 (-5.0 to -1.0)
SecondaryChange in Peak VO2 From Baseline to Week 12

Peak VO2 is assessed using a cardiopulmonary exercise test.

Time frame:
Baseline and Week 12
Reported as:
Mean · mL/kg/min
Change in Peak VO2 From Baseline to Week 12
mL/kg/minCohort ACohort B
Change in Peak VO2 From Baseline to Week 123.5 (1.2 to 5.9)1.7 (0.03 to 3.3)
SecondaryChange in VE/VCO2 From Baseline to Week 12

VE/VCO2 is assessed from cardiopulmonary exercise testing results.

Time frame:
Baseline and Week 12
Reported as:
Mean · Ratio
Change in VE/VCO2 From Baseline to Week 12
RatioCohort ACohort B
Change in VE/VCO2 From Baseline to Week 12-2.2 (-6.1 to 1.7)-2.5 (-4.3 to -0.7)
SecondaryChange in Resting LVEF From Baseline to Week 12

LVEF is assessed by echocardiography.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percent change
Change in Resting LVEF From Baseline to Week 12
Percent changeCohort ACohort B
Change in Resting LVEF From Baseline to Week 12-14.6 (-23.1 to -6.2)-5.5 (-9.8 to -1.2)
SecondaryChange in LV Fractional Shortening (LVFS) From Baseline to Week 12

LVFS is assessed using echocardiography measures.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percent
Change in LV Fractional Shortening (LVFS) From Baseline to Week 12
PercentCohort ACohort B
Change in LV Fractional Shortening (LVFS) From Baseline to Week 12-18.60 ± 13.05-3.98 ± 11.42
SecondaryChange in Global Longitudinal Strain (GLS) From Baseline to Week 12

GLS is assessed using echocardiography measures.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percent
Change in Global Longitudinal Strain (GLS) From Baseline to Week 12
PercentCohort ACohort B
Change in Global Longitudinal Strain (GLS) From Baseline to Week 120.56 ± 3.7780.18 ± 2.806
SecondaryChange in Post-exercise Peak LVOT Gradient From Week 12 to Week 16

Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.

Time frame:
Weeks 12 and 16
Reported as:
Mean · mm Hg
Change in Post-exercise Peak LVOT Gradient From Week 12 to Week 16
mm HgCohort ACohort B
Change in Post-exercise Peak LVOT Gradient From Week 12 to Week 1655.22 ± 40.8484.08 ± 28.38
Other pre-specifiedChange in NYHA Functional Class From Baseline to Week 12
Time frame:
Baseline and Week 12

Results for this outcome have not been posted.

Other pre-specifiedChange in KCCQ OSS From Baseline to Week 12
Time frame:
Baseline and Week 12

Results for this outcome have not been posted.

Other pre-specifiedChange in NT-proBNP From Baseline to Week 12
Time frame:
12 weeks

Results for this outcome have not been posted.

Other pre-specifiedNumber of Subjects Achieving an LVOT Gradient Response of Post-exercise Peak Gradient < 10 mmHg at Week 12

Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.

Time frame:
Baseline and Week 12

Results for this outcome have not been posted.

Adverse events

Collected over 16 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A0/11 (0%)1/11 (9.1%)10/11 (90.9%)
Cohort B0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventCohort ACohort B
Atrial FibrillationCardiac disorders1/110/10
Most frequent other events
Showing 10 of 73
Most frequent other events
EventCohort ACohort B
Ventricular TachycardiaCardiac disorders1/114/10
DizzinessNervous system disorders1/113/10
Atrial FibrillationCardiac disorders3/111/10
HeadacheNervous system disorders3/112/10
Ejection Fraction DecreasedInvestigations3/110/10
Angina PectorisCardiac disorders0/112/10
FatigueGeneral disorders2/112/10
Application Site RashGeneral disorders0/112/10
Upper Respiratory Tract InfectionInfections and infestations1/112/10
NauseaGastrointestinal disorders2/110/10

Baseline characteristics

Age, Customized
Age, Customized(years)Cohort ACohort BTotal
Mean Age (range)56 (22 to 70)58 (26 to 67)57 (22 to 70)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Cohort ACohort BTotal
Male7512
Female459
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ACohort BTotal
Hispanic or Latino000
Not Hispanic or Latino111021
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White11920
More than one race000
Unknown or Not Reported000
Postexercise LVOT gradient
Postexercise LVOT gradient(mm Hg)Cohort ACohort BTotal
Mean103 ± 5086 ± 4394.5 ± 0
08

Study locations

7 sites
  • Mayo Clinic Arizona
    Scottsdale, Arizona, United States
  • Yale New Haven Hospital
    New Haven, Connecticut, United States
  • Tufts Medical Center
    Boston, Massachusetts, United States
  • Washington University St. Louis
    St Louis, Missouri, United States
  • Duke Health Center at Southpoint
    Durham, North Carolina, United States
  • Oregon Health and Science University
    Portland, Oregon, United States
  • Hospital of the University of Pennsylvania (Penn Heart and Vascular Center)
    Philadelphia, Pennsylvania, United States
09

References and documents

Publications

  • Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, Lambing J, Lee J, Semigran M, Sehnert AJ. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Ann Intern Med. 2019 Jun 4;170(11):741-748. doi: 10.7326/M18-3016. Epub 2019 Apr 30. PubMed 31035291 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Nov 2017, 15 months.

Results were first posted in Feb 2020, 2 years 3 months after primary completion. A results delay was requested in Nov 2018.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Jul 22, 2016
StartActual
Aug 2016
Primary completionActual
Nov 2017
CompletionActual
Nov 2017
Results delay requested
Nov 19, 2018
Results first posted
Feb 5, 2020
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02842242
Lead sponsor
MyoKardia, Inc.
Responsible party
Sponsor
First posted
Jul 22, 2016
Start date
Aug 2016
Primary completion
Nov 2017
Completion
Nov 2017
Results posted
Feb 5, 2020
Last update
Jun 8, 2021

Study contacts

Amy Sehnert, MD
study chair · MyoKardia, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion